Cargando…

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

BACKGROUND: With the revolutionary progress of immune checkpoint inhibitors (ICIs) achieved in non-small cell lung cancers (NSCLC), identifying patients benefiting from ICIs becomes critical and urgent. The associations of genomic alterations in protein tyrosine phosphatase receptor-type (PTPRs) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yiting, Duan, Jianchun, Fang, Wenfeng, Wang, Zhijie, Du, Xinyang, Wang, Xin, Li, Chengcheng, Cai, Shangli, Zhao, Jie, Li, Sini, Zhang, Li, Bai, Hua, Wang, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496052/ https://www.ncbi.nlm.nih.gov/pubmed/34615542 http://dx.doi.org/10.1186/s12916-021-02075-5

Ejemplares similares

Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades
por: Wang, Xiaoyan, et al.
Publicado: (2021)

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
por: Hsu, Hung-Chih, et al.
Publicado: (2018)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Genetic variants in PTPRD and risk of gestational diabetes mellitus
por: Chen, Ting, et al.
Publicado: (2016)

Reduced Expression of PTPRD Correlates with Poor Prognosis in Gastric Adenocarcinoma
por: Wang, Dandan, et al.
Publicado: (2014)

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types
por: Shang, Xiaoling, et al.
Publicado: (2022)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas
por: Rautajoki, Kirsi J., et al.
Publicado: (2022)

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
por: Yang, Yin, et al.
Publicado: (2022)

Co-occurring genomic alterations and immunotherapy efficacy in NSCLC
por: Zhang, Fan, et al.
Publicado: (2022)

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
por: Qiu, Bin, et al.
Publicado: (2021)

Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis
por: Ortiz, Berenice, et al.
Publicado: (2014)

Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications
por: Jiang, Yunyun, et al.
Publicado: (2013)

Protein tyrosine phosphatase receptor type D (PTPRD)—mediated signaling pathways for the potential treatment of hepatocellular carcinoma: a narrative review
por: Huang, Xuejing, et al.
Publicado: (2020)

PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer
por: Ren, Zhixuan, et al.
Publicado: (2023)

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC
por: Wang, Bolin, et al.
Publicado: (2023)

Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy
por: Zhao, Jie, et al.
Publicado: (2023)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma
por: Bai, Hua, et al.
Publicado: (2020)

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
por: Tian, Yanhua, et al.
Publicado: (2020)

Protein tyrosine phosphatase receptor type delta (PTPRD) suppresses the expression of PD-L1 in human hepatocellular carcinoma by down-regulating STAT3
por: Meng, Qiuhua, et al.
Publicado: (2020)

Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies
por: Chibnik, Lori B, et al.
Publicado: (2017)

DIAPH2, PTPRD and HIC1 Gene Polymorphisms and Laryngeal Cancer Risk
por: Śnit, Mirosław, et al.
Publicado: (2021)

Comparison of the SuperARMS and Droplet Digital PCR for Detecting EGFR Mutation in ctDNA From NSCLC Patients
por: Feng, Wei-neng, et al.
Publicado: (2018)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Evidence that homozygous PTPRD gene microdeletion causes trigonocephaly, hearing loss, and intellectual disability
por: Choucair, Nancy, et al.
Publicado: (2015)

PTPRD silencing by DNA hypermethylation decreases insulin receptor signaling and leads to type 2 diabetes
por: Chen, Yng-Tay, et al.
Publicado: (2015)

PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin
por: Bae, Won Jung, et al.
Publicado: (2019)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer
por: Dong, Yiting, et al.
Publicado: (2022)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer
por: Tan, Qiaorui, et al.
Publicado: (2023)

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
por: Cai, Liangliang, et al.
Publicado: (2020)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

Mice lacking Ptprd exhibit deficits in goal-directed behavior and female-specific impairments in sensorimotor gating
por: Ho, Emily V., et al.
Publicado: (2023)

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
por: Zografos, Eleni, et al.
Publicado: (2022)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer
por: Peyser, Noah D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0rid94u1td7h6la516u064m57s